as of 08-17-2026 4:00pm EST
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 1.7B | IPO Year: | 2008 |
| Target Price: | $69.86 | AVG Volume (30 days): | 550.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.20 | EPS Growth: | 71.43 |
| 52 Week Low/High: | $28.54 - $54.98 | Next Earning Date: | 05-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 31.62% | Revenue Growth (next year): | 50.77% |
| P/E Ratio: | -33.36 | Index: | N/A |
| Free Cash Flow: | 43.0M | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$40.00
Shares
11,250
Total Value
$450,000.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Shojaei Amir | HROW | CHIEF SCIENTIFIC OFFICER | Aug 14, 2026 | Sell | $40.00 | 11,250 | $450,000.00 | 0 |
SEC 8-K filings with transcript text
Aug 10, 2026 · 100% conf.
1D
+12.25%
$45.69
Act: -3.14%
5D
+21.83%
$49.58
20D
+21.38%
$49.40
Transcript text not available. View on SEC.gov →
May 11, 2026
Mar 2, 2026
See how HROW stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "HROW Harrow Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.